Subscribe
Subscribe & Save!
Subscribe now and save 50% off the cover price of the Indianapolis Monthly magazine.
×

Eli Lilly

Read More

The Complete Guide To Indy’s Burgeoning Podcast-Industrial Complex

Whether you have a taste for murder, could use a stiff drink, or just want some company on a run, we have the right local podcast for you.

Read More

Lilly’s Chief Scientific Officer On COVID-19: “I Don’t Think We’ll Eradicate It”

“I don’t foresee us going back to the way things were anytime soon.”

Read More

Why Indiana Doesn’t Want This Indianapolis Lab’s Coronavirus Test Kits

“Our first priority is our community, our city, and the state.”

Read More

Indy’s Bicentennial: A Year Of Celebrations

Toast to the town.

Read More

Mike Dalton, Eli Lilly Chemist

At the pharmaceutical giant, Dalton’s job is to thwart counterfeiters, who can be a real pill.

Read More

Eli Lilly’s Hazy Memory

A century ago, Eli Lilly and Company grew one of the nation’s largest cannabis farms to supply a variety of pharmaceuticals. Why does the drug maker seem determined to conceal the details of that history?

default featured image
Read More

The Unblinding: Has Lilly Solved the Alzheimer’s Puzzle? — An Epilogue

The search continues.

default featured image
Read More

December Foodie: Pia Urban Cafe’s Maria Cartagena

Look behind the counter for the truest sign of Cartagena’s mission: Her team includes graduates of the Wheeler Mission residential program.

Read More

The Unblinding: Has Lilly Solved The Alzheimer’s Puzzle?

Eli Lilly and Company has spent three decades and $3 billion in an Ahab-like quest to develop the world’s first effective drug to treat Alzheimer’s disease.

scaletowidth.png
Read More

Culture Warriors: LGBT Battlefield

“RFRA was embarrassing, but Pence hasn’t won elections by championing LGBT causes. And he still wields the veto pen, which is mighty indeed.”

default featured image
Read More

Life after Zyprexa: the Future of Eli Lilly and Company

“We want high quality of life as long as possible, don’t we?” says Lilly executive Jan Lundberg. “Many of our current diseases are chronic, and they accumulate with age, so there are major demands coming from the aging population.”

Zyprexa
Read More

Side Effects

With thousands of medical success stories and billions in revenue, officials at Lilly are still celebrating the success of Zyprexa. But its troubled path reveals volumes about how difficult bringing even an approved medication to market can turn out to be.

X
X